Skip to main content
Top
Published in: Clinical Rheumatology 5/2013

01-05-2013 | Original Article

An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing

Authors: Ada Man, Kam Shojania, Carmen Phoon, Jason Pal, Monika Hudoba de Badyn, David Pi, Diane Lacaille

Published in: Clinical Rheumatology | Issue 5/2013

Login to get access

Abstract

Autoantibody tests are often ordered inappropriately. We aimed to evaluate the ordering patterns of these tests in our local health region and to develop a laboratory algorithm aimed at reducing unnecessary tests. Laboratory data including the number and sequence of tests, ordering physician specialties and results for antinuclear (ANA), extractable nuclear antigen (ENA) and anti-double stranded DNA (anti-dsDNA) antibody tests from 2007 to 2009 were evaluated. Based on this information and a clinical consensus meeting, an algorithm was developed and applied retrospectively to 1 year of inpatient laboratory data to simulate potential cost savings. We identified a large volume of these autoantibody tests performed, equating to testing costs of $862,706.72, where less than 17 % of each were positive. Repeated ANA tests were mostly ordered after a previously negative result, and 1 % of patients with negative results changed to ≥1:160 on repeat testing. Close to half of all ENA and anti-dsDNA tests that were ordered were done so simultaneously with ANA, suggesting their use as screening tests. This was done more frequently in the inpatient setting. An algorithm was developed where ENA and anti-dsDNA tests would be cancelled if ANA was negative in the same sample. ANA repeated within 1 year would be cancelled and the prior result provided. Application of the algorithm retrospectively simulated a 30 % cost savings. Repeat testing and simultaneous ordering of multiple tests contributed to the excessive ordering of autoantibody tests in our health region. Our proposed algorithm would reduce testing costs and should be accompanied by appropriate educational information for physicians.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tan EM, Feltkamp TE, Smolen JS et al (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40(9):1601–1611PubMedCrossRef Tan EM, Feltkamp TE, Smolen JS et al (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40(9):1601–1611PubMedCrossRef
2.
go back to reference Tampoia M, Brescia V, Fontana A et al (2007) Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficacy in autoimmune rheumatic disease. Arch Pathol Lab Med 131(1):112–116PubMed Tampoia M, Brescia V, Fontana A et al (2007) Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficacy in autoimmune rheumatic disease. Arch Pathol Lab Med 131(1):112–116PubMed
3.
go back to reference Solomon DH, Shmerling RH, Schur PH et al (1999) A computer based intervention to reduce unnecessary serologic testing. J Rheumatol 26(12):2578–2584PubMed Solomon DH, Shmerling RH, Schur PH et al (1999) A computer based intervention to reduce unnecessary serologic testing. J Rheumatol 26(12):2578–2584PubMed
4.
go back to reference Bonaguri C, Melegari A, Dall’Aglio P et al (2009) An Italian multicenter study for application of a diagnostic algorithm in autoantibody testing. Ann N Y Acad Sci 1173:124–129PubMedCrossRef Bonaguri C, Melegari A, Dall’Aglio P et al (2009) An Italian multicenter study for application of a diagnostic algorithm in autoantibody testing. Ann N Y Acad Sci 1173:124–129PubMedCrossRef
5.
go back to reference Wiik A, Cervera R, Haass M et al (2006) European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders. Lupus 15(7):391–396PubMedCrossRef Wiik A, Cervera R, Haass M et al (2006) European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders. Lupus 15(7):391–396PubMedCrossRef
6.
go back to reference Tozzoli R, Bizzaro N, Tonutti E et al (2002) Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 117(2):316–324PubMedCrossRef Tozzoli R, Bizzaro N, Tonutti E et al (2002) Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 117(2):316–324PubMedCrossRef
7.
go back to reference Stinton LM, Fritzler MJ (2007) A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmun Rev 7(1):77–84PubMedCrossRef Stinton LM, Fritzler MJ (2007) A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmun Rev 7(1):77–84PubMedCrossRef
8.
go back to reference Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 124(1):71–81PubMed Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 124(1):71–81PubMed
9.
go back to reference Shojania K (2000) Rheumatology: 2. What laboratory tests are needed? CMAJ 162(8):1157–1163PubMed Shojania K (2000) Rheumatology: 2. What laboratory tests are needed? CMAJ 162(8):1157–1163PubMed
10.
go back to reference Bizzaro N, Wiik A (2004) Appropriateness in anti-nuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol 22(3):349–355PubMed Bizzaro N, Wiik A (2004) Appropriateness in anti-nuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol 22(3):349–355PubMed
12.
go back to reference Solomon DH, Kavanaugh AJ, Schur PH (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47(4):434–444PubMedCrossRef Solomon DH, Kavanaugh AJ, Schur PH (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47(4):434–444PubMedCrossRef
13.
go back to reference Avina-Zubieta JA, Sayre EC, Bernatsky S et al (2011) Adult Prevalence of Systemic Autoimmune Rheumatic Diseases (SARDs) in British Columbia. Can Arthritis Rheum 63(Suppl 10):1846 Avina-Zubieta JA, Sayre EC, Bernatsky S et al (2011) Adult Prevalence of Systemic Autoimmune Rheumatic Diseases (SARDs) in British Columbia. Can Arthritis Rheum 63(Suppl 10):1846
16.
go back to reference Wiik AS (2005) Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 34(4):260–268PubMedCrossRef Wiik AS (2005) Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 34(4):260–268PubMedCrossRef
17.
go back to reference Dahle C, Skogh T, Aberg AK, Jalal A, Olcén P (2004) Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun 22(3):241–248PubMedCrossRef Dahle C, Skogh T, Aberg AK, Jalal A, Olcén P (2004) Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun 22(3):241–248PubMedCrossRef
18.
go back to reference Peene I, Meheus L, Veys E, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60(12):1131–1136PubMedCrossRef Peene I, Meheus L, Veys E, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60(12):1131–1136PubMedCrossRef
19.
20.
go back to reference Fritzler MJ, Miller BJ (1995) Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. J Clin Lab Anal 9(3):218–224PubMedCrossRef Fritzler MJ, Miller BJ (1995) Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. J Clin Lab Anal 9(3):218–224PubMedCrossRef
21.
go back to reference Fritzler MJ, Wiik A, Fritzler ML, Barr SG (2003) The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 5(4):192–201PubMedCrossRef Fritzler MJ, Wiik A, Fritzler ML, Barr SG (2003) The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 5(4):192–201PubMedCrossRef
22.
go back to reference Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69(8):1420–1422PubMedCrossRef Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69(8):1420–1422PubMedCrossRef
Metadata
Title
An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing
Authors
Ada Man
Kam Shojania
Carmen Phoon
Jason Pal
Monika Hudoba de Badyn
David Pi
Diane Lacaille
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-2141-y

Other articles of this Issue 5/2013

Clinical Rheumatology 5/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.